Peanut Consumption and Cardiovascular Disease Risk in a Chinese Population

February 27, 2019 updated by: Vasanti Malik, Harvard School of Public Health (HSPH)

Effects of Peanut Consumption on Cardiovascular Disease Risk Factors and Gut Microbiota Among Adults in China: A Randomized Controlled Trial

This is a 2 parallel-arm randomized controlled study with free-living subjects on self-selected diets. The objective of this study is to compare the effects of two servings of peanuts with an isocaloric matched refined carbohydrate snack food on glucose, lipids and lipoproteins and cardiovascular health risk factors, satiety and gut microbiota in 250 Chinese participants at risk for metabolic syndrome (overweight/obese, enlarged waist circumference, elevated LDL-cholesterol, prehypertension, and/or prediabetes).

The investigators hypothesize that the inclusion of 2 serving of peanuts in the diet will decrease blood glucose, LDL-cholesterol, and improve satiety sanctification between meals and gut microbiota compared to the control group and baseline.

Study Overview

Status

Completed

Conditions

Detailed Description

Emerging evidence has shown that peanut consumption has beneficial effects in modifying lipid profiles, glucose, and other cardiometabolic risk factors. During the last two decades, China has experienced a dramatic increase in T2D prevalence largely due to rapid social and economic growth. Peanuts are commonly consumed as snacks in China. However, there is limited evidence on the specific health benefits of peanuts as part of the Chinese habitual diet.

Clinical Study Protocol

Study diet Subjects will consume their habitual diet with the test snacks provided as roasted peanuts and rice flour snack bars twice a day during a mid- morning snack and mid -afternoon snack. Subjects in the peanut group will consume two serving of peanuts and subjects in the control group will consume isocaloric rice bars on a daily basis under on site supervision. Subjects will be instructed to maintain their habitual diet and physical activity. During the study period, body weight will be monitored routinely to ensure that baseline weight does not fluctuate by more than 1kg. Prior to day 1, day 42 and day 84, a three-day diet record will be administered to subjects to calculate basal energy intake.

Study design The study is a randomized, controlled, parallel-arm trial precedes by a 1-week run-in period with control treatment to assess compliance, acceptability and to determine baseline values.After the run-in period, participants will be randomized to either the control group or treatment group for three months. Each treatment phase will be 3 months in duration. At baseline, day 42 and day 84, clinical assessment (body weight, waist/hip circumference, blood pressure, pulse) will be preformed and blood samples will be collected. Urinary will be collected on baseline, day 42 and day 84. Fecal samples will be collected on baseline and day 84. Three days dietary records and appetite sensation ratings will be collected three times during the study (baseline, day 42 and day 84).

Study Type

Interventional

Enrollment (Actual)

238

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Shanghai, China, 200040
        • Liang Sun

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

20 years to 65 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • 20-65
  • Increased waist circumference : ≥ 90 cm for men and ≥ 80 cm for women

Plus 1 or more of the remaining criteria:

  • Elevated TG level ≥ 1.7 mmo/L
  • Reduced HDL-Cholesterol < 1.03 mmol/L in men and < 1.29 mmol/L in women)
  • Fasting glucose ≥ 5.6 mmol/L
  • Systolic/diastolic blood pressure ≥ 130/85 mmHg.

Exclusion Criteria:

  • Taking lipid lowering medications
  • With known or unknown peanut allergy (or any peanut containing products)
  • Thyroid disease
  • Diabetes mellitus
  • Kidney disease
  • Liver disease
  • Cardiovascular disease or cancer
  • Pregnant or lactating women
  • Heavy alcohol consumption (>14 drinks/week)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Peanut
Daily consumption of 2 servings of roasted peanuts for 12 weeks Intervention: Dietary Supplement: Roasted peanuts
Dietary Supplement: Peanut
Experimental: Control
Daily consumption of isocaloric matched snack food for 12 weeks Intervention: Other: High Carbohydrate Snack
Dietary Supplement: High carbohydrate snacks

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Blood glucose
Time Frame: Blood glucose will be measured at day 84.
glucose, insulin, HbA1c
Blood glucose will be measured at day 84.

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Blood lipids level
Time Frame: Blood lipids level will be measured at day 84.
cholesterol and triglyceride levels
Blood lipids level will be measured at day 84.
Blood Inflammatory status
Time Frame: Inflammatory biomarkers will be measured at day 84.
Inflammatory biomarkers
Inflammatory biomarkers will be measured at day 84.
Assessment of appetite and other hunger sensations
Time Frame: Appetite and other hunger sensations will be measured at day 84.
Appetite and other hunger sensations will be assessed using visual analogue scales
Appetite and other hunger sensations will be measured at day 84.
Microbiome
Time Frame: Micriobiome will be measured at day 84.
fecal microbiome (subset) A subset of study subjects will be measured for fecal microbiome functionality.
Micriobiome will be measured at day 84.
Polyphenol metabolites
Time Frame: Polyphenol metabolites will be measured at day 84.
Urinary polyphenol metabolites (subset)
Polyphenol metabolites will be measured at day 84.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Xiaoran Liu, PhD, Harvard School of Public Health (HSPH)

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

October 24, 2017

Primary Completion (Actual)

March 1, 2018

Study Completion (Actual)

March 1, 2018

Study Registration Dates

First Submitted

June 5, 2017

First Submitted That Met QC Criteria

June 19, 2017

First Posted (Actual)

June 21, 2017

Study Record Updates

Last Update Posted (Actual)

February 28, 2019

Last Update Submitted That Met QC Criteria

February 27, 2019

Last Verified

February 1, 2019

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • IRB17-0703

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on T2D

Clinical Trials on Peanut

3
Subscribe